Difference between revisions of "Offermann A, et al. Oncotarget (2017) cited as Ref 363 in DOI: 10.1038/s41392-020-0110-5 (Q9626)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 8, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling (English) | ||
| Property / title: MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:00, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Offermann A, et al. Oncotarget (2017) cited as Ref 363 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Offermann A
0 references
2017
0 references
Oncotarget
0 references
8
0 references
MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling (English)
0 references
